Skip to Content

Aeolus Pharmaceuticals Inc AOLS

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AOLS is trading at a 87% premium.
Price
$0.00
Fair Value
$5.26
Uncertainty
Extreme
1-Star Price
$1.55
5-Star Price
$4.42
Economic Moat
Kqwwcy
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AOLS is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.01
Market Cap
$152.09
Volume/Avg
10,898 / 6,449

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Aeolus Pharmaceuticals Inc is a Southern California based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
4

Valuation

Metric
AOLS
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
AOLS
Quick Ratio
1.22
Current Ratio
1.30
Interest Coverage
Quick Ratio
AOLS

Profitability

Metric
AOLS
Return on Assets (Normalized)
−143.67%
Return on Equity (Normalized)
−188.68%
Return on Invested Capital (Normalized)
−188.68%
Return on Assets
AOLS
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
HtycgmczMgjt$83.5 Bil
Merck KGaA ADR
MKKGY
CstwcbdxVcqhbll$73.0 Bil
Haleon PLC ADR
HLN
DdgpbwydNnqq$39.3 Bil
Teva Pharmaceutical Industries Ltd ADR
TEVA
FxzcsldlCdth$19.6 Bil
Viatris Inc
VTRS
SyrtwhdNlhr$13.5 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
HlczjylsCchq$13.2 Bil
Catalent Inc
CTLT
FzkpgdvNcdjpx$10.5 Bil
Perrigo Co PLC
PRGO
SmgpdmwbLsx$3.7 Bil
Prestige Consumer Healthcare Inc
PBH
VnjjxmsydWdmhzn$3.6 Bil
Curaleaf Holdings Inc
CURLF
YgplnwmNkd$3.2 Bil

Sponsor Center